Search Results Search Sort by RelevanceMost Recent Viewpoint Dec 2019 Genome Editing, Ethics, and Politics Isabel Gabel, PhD and Jonathan Moreno, PhD Genome editing raises old questions, but CRISPR arose in a political landscape that vastly differs from the early aughts. AMA J Ethics. 2019;21(12):E1105-1110. doi: 10.1001/amajethics.2019.1105. Policy Forum Dec 2005 Physician-Advocate: Deciding What To Fight for and When Philip A. Pizzo, MD Virtual Mentor. 2005;7(12):813-815. doi: 10.1001/virtualmentor.2005.7.12.pfor2-0512. Medicine and Society Dec 2005 A Doctor in the House Dave Weldon, MD Virtual Mentor. 2005;7(12):826-827. doi: 10.1001/virtualmentor.2005.7.12.msoc4-0512. Medicine and Society Dec 2005 Assessing Physician Legislators Allison Grady Virtual Mentor. 2005;7(12):828-835. doi: 10.1001/virtualmentor.2005.7.12.msoc5-0512. Case and Commentary Jan 2004 Campaign Posters in the Clinic, Commentary 1 Marion Danis, MD Virtual Mentor. 2004;6(1):6-8. doi: 10.1001/virtualmentor.2004.6.1.ccas1-0401. Case and Commentary Jan 2004 Campaign Posters in the Clinic, Commentary 2 Leonard M. Fleck, PhD Virtual Mentor. 2004;6(1):9-11. doi: 10.1001/virtualmentor.2004.6.1.ccas1-0401. Case and Commentary Jan 2004 Physician Activism and Civil Disobedience, Commentary 2 Barry DeCoster, MA Virtual Mentor. 2004;6(1):20-23. doi: 10.1001/virtualmentor.2004.6.1.ccas3-0401. Medicine and Society Jan 2004 Beyond Medical School: The Frontier of Medical Activism Braden Hexom Virtual Mentor. 2004;6(1):51-53. doi: 10.1001/virtualmentor.2004.6.1.msoc2-0401. Viewpoint Jan 2004 Activism? Yes! The AMA? Maybe Not Howard Brody, MD, PhD Virtual Mentor. 2004;6(1):60-62. doi: 10.1001/virtualmentor.2004.6.1.oped1-0401. Viewpoint Apr 2014 Inappropriate Obstructions to Access: The FDA’s Handling of Plan B Susan F. Wood, PhD The FDA’s approval for over-the-counter sales of emergency contraception marked a departure from its standard approval process and obstructed access to a safe and effective drug. That departure could set a dangerous precedent for future decisions. Virtual Mentor. 2014;16(4):295-301. doi: 10.1001/virtualmentor.2014.16.4.oped1-1404. Pagination Current page 1 Page 2 Next page Next › Last page Last »
Viewpoint Dec 2019 Genome Editing, Ethics, and Politics Isabel Gabel, PhD and Jonathan Moreno, PhD Genome editing raises old questions, but CRISPR arose in a political landscape that vastly differs from the early aughts. AMA J Ethics. 2019;21(12):E1105-1110. doi: 10.1001/amajethics.2019.1105.
Policy Forum Dec 2005 Physician-Advocate: Deciding What To Fight for and When Philip A. Pizzo, MD Virtual Mentor. 2005;7(12):813-815. doi: 10.1001/virtualmentor.2005.7.12.pfor2-0512.
Medicine and Society Dec 2005 A Doctor in the House Dave Weldon, MD Virtual Mentor. 2005;7(12):826-827. doi: 10.1001/virtualmentor.2005.7.12.msoc4-0512.
Medicine and Society Dec 2005 Assessing Physician Legislators Allison Grady Virtual Mentor. 2005;7(12):828-835. doi: 10.1001/virtualmentor.2005.7.12.msoc5-0512.
Case and Commentary Jan 2004 Campaign Posters in the Clinic, Commentary 1 Marion Danis, MD Virtual Mentor. 2004;6(1):6-8. doi: 10.1001/virtualmentor.2004.6.1.ccas1-0401.
Case and Commentary Jan 2004 Campaign Posters in the Clinic, Commentary 2 Leonard M. Fleck, PhD Virtual Mentor. 2004;6(1):9-11. doi: 10.1001/virtualmentor.2004.6.1.ccas1-0401.
Case and Commentary Jan 2004 Physician Activism and Civil Disobedience, Commentary 2 Barry DeCoster, MA Virtual Mentor. 2004;6(1):20-23. doi: 10.1001/virtualmentor.2004.6.1.ccas3-0401.
Medicine and Society Jan 2004 Beyond Medical School: The Frontier of Medical Activism Braden Hexom Virtual Mentor. 2004;6(1):51-53. doi: 10.1001/virtualmentor.2004.6.1.msoc2-0401.
Viewpoint Jan 2004 Activism? Yes! The AMA? Maybe Not Howard Brody, MD, PhD Virtual Mentor. 2004;6(1):60-62. doi: 10.1001/virtualmentor.2004.6.1.oped1-0401.
Viewpoint Apr 2014 Inappropriate Obstructions to Access: The FDA’s Handling of Plan B Susan F. Wood, PhD The FDA’s approval for over-the-counter sales of emergency contraception marked a departure from its standard approval process and obstructed access to a safe and effective drug. That departure could set a dangerous precedent for future decisions. Virtual Mentor. 2014;16(4):295-301. doi: 10.1001/virtualmentor.2014.16.4.oped1-1404.